Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF

Science Signaling

Volumn 4, Issue 190, 2011, Pages

  Andreu Pérez, Pedro ^a   Esteve Puig, Rosaura ^a   De Torre Minguela, Carlos ^a,d   López Fauqued, Marta ^a   Bech Serra, Joan Josep ^a   Tenbaum, Stephan ^a   García Trevijano, Elena R ^b,e   Canals, Francesc ^a   Merlino, Glenn ^c   Ávila, Matías A ^b   Recio, Juan A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 5; RAF PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; BRAF PROTEIN, RAT; EPIDERMAL GROWTH FACTOR; MAPK1 PROTEIN, HUMAN; NERVE GROWTH FACTOR; NGF PROTEIN, HUMAN; PRMT5 PROTEIN, HUMAN; PROTEIN METHYLTRANSFERASE;

ARTICLE; CATALYSIS; CELL DIFFERENTIATION; CELL FATE; HUMAN; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN COS1; CELL STRAIN HEK293; CERCOPITHECUS; DRUG EFFECT; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RAT;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; EPIDERMAL GROWTH FACTOR; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NERVE GROWTH FACTOR; PC12 CELLS; PHOSPHORYLATION; PROTEIN METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RATS;

EID: 80052943618     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001936     Document Type: Article

References (56)

1. T. S. Lewis, P. S. Shapiro, N. G. Ahn, Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139 (1998).
2. Human gene symbols are italicized, with all letters in uppercase. Protein designations are the same as the gene symbol, but are not italicized; all letters are in uppercase. mRNAs and cDNAs use the same formatting conventions as the gene symbol. Mouse and rat gene symbols are italicized, with only the first letter in uppercase and the remaining letters in lowercase. Protein designations are the same as the gene symbol, but are not italicized, all uppercase letters.
3. B. J. Canagarajah, A. Khokhlatchev, M. H. Cobb, E. J. Goldsmith, Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90, 859-869 (1997).
4. J. J. Hornberg, B. Binder, F. J. Bruggeman, B. Schoeberl, R. Heinrich, H. V. Westerhoff, Control of MAPK signalling: From complexity to what really matters. Oncogene 24, 5533-5542 (2005).
5. J. J. Hornberg, F. J. Bruggeman, B. Binder, C. R. Geest, A. J. De Vaate, J. Lankelma, R. Heinrich, H. V. Westerhoff, Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control. FEBS J. 272, 244-258 (2005).
6. N. D. Perkins, Post-translational modifications regulating the activity and function of the nuclear factor kB pathway. Oncogene 25, 6717-6730 (2006).
7. T. Okada, T. Masuda, M. Shinkai, K. Kariya, T. Kataoka, Post-translational modification of H-Ras is required for activation of, but not for association with, B-Raf. J. Biol. Chem. 271, 4671-4678 (1996).
8. G. Hatzivassiliou, K. Song, I. Yen, B. J. Brandhuber, D. J. Anderson, R. Alvarado, M. J. Ludlam, D. Stokoe, S. L. Gloor, G. Vigers, T. Morales, I. Aliagas, B. Liu, S. Sideris, K. P. Hoeflich, B. S. Jaiswal, S. Seshagiri, H. Koeppen, M. Belvin, L. S. Friedman, S. Malek, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
9. P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, N. Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
10. S. J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, N. Dhomen, J. Hussain, J. S. Reis-Filho, C. J. Springer, C. Pritchard, R. Marais, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
11. A. E. McBride, P. A. Silver, State of the Arg: Protein methylation at arginine comes of age. Cell 106, 5-8 (2001).
12. M. T. Bedford, S. Richard, Arginine methylation an emerging regulator of protein function. Mol. Cell 18, 263-272 (2005).
13. M. T. Bedford, S. G. Clarke, Protein arginine methylation in mammals: Who, what, and why. Mol. Cell 33, 1-13 (2009).
14. T. L. Branscombe, A. Frankel, J. H. Lee, J. R. Cook, Z. Yang, S. Pestka, S. Clarke, PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J. Biol. Chem. 276, 32971-32976 (2001).
15. Y. H. Lee, M. R. Stallcup, Minireview: Protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol. Endocrinol. 23, 425-433 (2009).
16. S. Richard, M. Morel, P. Cleroux, Arginine methylation regulates IL-2 gene expression: A role for protein arginine methyltransferase 5 (PRMT5). Biochem. J. 388, 379-386 (2005).
17. S. Amente, G. Napolitano, P. Licciardo, M. Monti, P. Pucci, L. Lania, B. Majello, Identification of proteins interacting with the RNAPII FCP1 phosphatase: FCP1 forms a complex with arginine methyltransferase PRMT5 and it is a substrate for PRMT5-mediated methylation. FEBS Lett. 579, 683-689 (2005).
18. W. J. Friesen, A. Wyce, S. Paushkin, L. Abel, J. Rappsilber, M. Mann, G. Dreyfuss, A novelWD repeat protein component of the methylosome binds Sm proteins. J. Biol. Chem. 277, 8243-8247 (2002).
19. A. Maloney, P. A. Clarke, S. Naaby-Hansen, R. Stein, J. O. Koopman, A. Akpan, A. Yang, M. Zvelebil, R. Cramer, L. Stimson, W. Aherne, U. Banerji, I. Judson, S. Sharp, M. Powers, E. DeBilly, J. Salmons, M. Walton, A. Burlingame, M. Waterfield, P. Workman, Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67, 3239-3253 (2007).
20. J. Rho, S. Choi, Y. R. Seong, W. K. Cho, S. H. Kim, D. S. Im, PRMT5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family. J. Biol. Chem. 276, 11393-11401 (2001).
21. B. P. Pollack, S. V. Kotenko, W. He, L. S. Izotova, B. L. Barnoski, S. Pestka, The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J. Biol. Chem. 274, 31531-31542 (1999).
22. H. Tanaka, Y. Hoshikawa, T. Oh-hara, S. Koike, M. Naito, T. Noda, H. Arai, T. Tsuruo, N. Fujita, PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kB activation. Mol. Cancer Res. 7, 557-569 (2009).
23. M. Gilbreth, P. Yang, D. Wang, J. Frost, A. Polverino, M. H. Cobb, S. Marcus, The highly conserved skb1 gene encodes a protein that interacts with Shk1, a fission yeast Ste20/PAK homolog. Proc. Natl. Acad. Sci. U.S.A. 93, 13802-13807 (1996).
24. C. Birchmeier, W. Birchmeier, E. Gherardi, G. F. Vande Woude, Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925 (2003).
25. M. L. Martínez-Chantar, M. U. Latasa, M. Varela-Rey, S. C. Lu, E. R. García-Trevijano, J. M. Mato, M. A. Avila, L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: Role of S-adenosylmethionine. J. Biol. Chem. 278, 19885-19890 (2003).
26. S. Chuikov, J. K. Kurash, J. R. Wilson, B. Xiao, N. Justin, G. S. Ivanov, K. McKinney, P. Tempst, C. Prives, S. J. Gamblin, N. A. Barlev, D. Reinberg, Regulation of p53 activity through lysine methylation. Nature 432, 353-360 (2004).
27. C. Martin, Y. Zhang, The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838-849 (2005).
28. I. H. Su, M. W. Dobenecker, E. Dickinson, M. Oser, A. Basavaraj, R. Marqueron, A. Viale, D. Reinberg, C. Wülfing, A. Tarakhovsky, Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121, 425-436 (2005).
29. C. D. Krause, Z. H. Yang, Y. S. Kim, J. H. Lee, J. R. Cook, S. Pestka, Protein arginine methyltransferases: Evolution and assessment of their pharmacological and therapeutic potential. Pharmacol. Ther. 113, 50-87 (2007).
30. N. Dumaz, R. Hayward, J. Martin, L. Ogilvie, D. Hedley, J. A. Curtin, B. C. Bastian, C. Springer, R. Marais, In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 9483-9491 (2006).
31. S. Y. Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box, T. P. Matthews, K. M. Cheung, A. Kalusa, K. James, A. Hayes, A. Hardcastle, B. Dymock, P. A. Brough, X. Barril, J. E. Cansfield, L. Wright, A. Surgenor, N. Foloppe, R. E. Hubbard, W. Aherne, L. Pearl, K. Jones, E. McDonald, F. Raynaud, S. Eccles, M. Drysdale, P. Workman, Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 6, 1198-1211 (2007).
32. C. Noble, K. Mercer, J. Hussain, L. Carragher, S. Giblett, R. Hayward, C. Patterson, R. Marais, C. A. Pritchard, CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol. Cell 31, 862-872 (2008).
33. B. Hallberg, S. I. Rayter, J. Downward, Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J. Biol. Chem. 269, 3913-3916 (1994).
34. S. Kao, R. K. Jaiswal, W. Kolch, G. E. Landreth, Identification of the mechanisms regulating the differential activation of the MAPK cascade by epidermal growth factor and nerve growth factor in PC12 cells. J. Biol. Chem. 276, 18169-18177 (2001).
35. S. Traverse, N. Gomez, H. Paterson, C. Marshall, P. Cohen, Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 288, 351-355 (1992).
36. C. J. Marshall, Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal - regulated kinase activation. Cell 80, 179-185 (1995).
37. R. M. Tombes, K. L. Auer, R. Mikkelsen, K. Valerie, M. P. Wymann, C. J. Marshall, M. McMahon, P. Dent, The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem. J. 330, 1451-1460 (1998).
38. G. Pearson, F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K. Berman, M. H. Cobb, Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev. 22, 153-183 (2001).
39. 1, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet. 86, 22-28 (1996).
40. I. Behrmann, S. Wallner, W. Komyod, P. C. Heinrich, M. Schuierer, R. Buettner, A. K. Bosserhoff, Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am. J. Pathol. 163, 683-690 (2003).
41. M. A. Avila, E. R. Garcia-Trevijano, S. C. Lu, F. J. Corrales, J. M. Mato, Methylthioadenosine. Int. J. Biochem. Cell Biol. 36, 2125-2130 (2004).
42. A. P. Stevens, K. Dettmer, S. Wallner, A. K. Bosserhoff, P. J. Oefner, Quantitative analysis of 5′-deoxy-5′-methylthioadenosine in melanoma cells by liquid chromatographystable isotope ratio tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876, 123-128 (2008).
43. J. Tang, A. Frankel, R. J. Cook, S. Kim, W. K. Paik, K. R. Williams, S. Clarke, H. R. Herschman, PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J. Biol. Chem. 275, 7723-7730 (2000).
44. C. Wellbrock, M. Karasarides, R. Marais, The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885 (2004).
45. S. D. Santos, P. J. Verveer, P. I. Bastiaens, Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat. Cell Biol. 9, 324-330 (2007).
46. P. J. Roberts, C. J. Der, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310 (2007).
47. R. Esteve-Puig, F. Canals, N. Colomé, G. Merlino, J. A. Recio, Uncoupling of the LKB1-AMPKa energy sensor pathway by growth factors and oncogenic BRAFV600E. PLoS One 4, e4771 (2009).
48. E. R. García-Trevijano, M. L. Martínez-Chantar, M. U. Latasa, J. M. Mato, M. A. Avila, NO sensitizes rat hepatocytes to proliferation by modifying S-adenosylmethionine levels. Gastroenterology 122, 1355-1363 (2002).
49. P. T. Wan, M. J. Garnett, S. M. Roe, S. Lee, D. Niculescu-Duvaz, V. M. Good, C.M. Jones, C. J. Marshall, C. J. Springer, D. Barford, R. Marais; Cancer Genome Project, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
50. Q. Liu, G. Dreyfuss, In vivo and in vitro arginine methylation of RNA-binding proteins. Mol. Cell. Biol. 15, 2800-2808 (1995).
51. C. Abramovich, B. Yakobson, J. Chebath, M. Revel, A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J. 16, 260-266 (1997).
52. K. A. Mowen, J. Tang, W. Zhu, B. T. Schurter, K. Shuai, H. R. Herschman, M. David, Arginine methylation of STAT1 modulates IFNa/b-induced transcription. Cell 104, 731-741 (2001).
53. M. Jansson, S. T.Durant,E.C.Cho, S. Sheahan, M. Edelmann, B. Kessler,N.B. La Thangue, Arginine methylation regulates the p53 response. Nat. Cell Biol. 10, 1431-1439 (2008).
54. L. New, Y. Li, B. Ge, H. Zhong, J. Mansbridge, K. Liu, J. Han, SB203580 promotes EGF-stimulated early morphological differentiation in PC12 cell through activating ERK pathway. J. Cell. Biochem. 83, 585-596 (2001).
55. N. Colomé, J. Collado, J. J. Bech-Serra, I. Liiv, L. C. Anton, P. Peterson, F. Canals, D. Jaraquemada, I. Alvarez, Increased apoptosis after autoimmune regulator expression in epithelial cells revealed by a combined quantitative proteomics approach. J. Proteome Res. 9, 2600-2609 (2010).
56. Acknowledgments: We thank J. Seoane, J. C. Rodriguez-Manzanque, and C. Jhappan for useful discussions and reading the manuscript. Funding: This work was supported in part by Instituto de Salud Carlos III grants PI-050227 and PI-080653 (J.A.R.) and ISCIII-RTICC RD06/00200061 PI070392 and PI10/00038 (M.A.A.), Marie Curie Reintegration grant MIRG-CT-2005-029135 (J.A.R.), Fundación Mutua Madrileña and Fundación Segunda Opinión en Oncología (FUSEON) (J.A.R.), Ministerio de Educación y Ciencia SAF 2004-03538 (M.A.A.), UTE project CIMA (M.A.A.), and the Intramural Research Program of the NIH, National Cancer Institute, and Center for Cancer Research (G.M.). Author contributions: P.A.-P., R.E.-P., and C.T.-M. designed and performed the experiments and analyzed the data. M.L.-F., J.J.B.-S., S.T., and E.R.G.-T. performed the experiments. F.C. designed the experiments and wrote the paper. G.M. analyzed the data and wrote the paper. M.A.A. designed the experiments, analyzed the data, and wrote the paper. J.A.R. designed and performed the experiments, analyzed the data, and wrote the paper. Competing interests: The authors declare that they have no competing interests.